Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced ovarian epithelial cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborator: National Cancer Institute (NCI)
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Cisplatin; Paclitaxel; Topotecan

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed advanced ovarian epithelial carcinoma, regardless of quantity of disease post-surgery

• Stage IC, II, III, or IV

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• SGOT no greater than 3 times upper limit of normal

• Bilirubin no greater than 2.0 mg/dL

• No clinically significant hepatic disorder

Renal:

• Creatinine no greater than 1.5 mg/dL OR

• Creatinine clearance greater than 60 mL/min

• No clinically significant renal disorder

Cardiovascular:

• No clinically significant cardiovascular condition

Other:

• Normal GI function allowing reliable administration of oral medication

• No active infection requiring systemic medical therapy within past week

• No other clinically significant medical condition (e.g., endocrine/metabolic or autoimmune disorder)

• No other prior malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix

• No dementia or altered mental status that would preclude consent

• Not pregnant

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for ovarian epithelial carcinoma

Endocrine therapy:

• Not specified

Radiotherapy:

• No prior radiotherapy for ovarian epithelial carcinoma

Surgery:

• See Disease Characteristics